What do systematic reviews say?

Intervention not reported

The intervention may leads to higher anaemia grade 3 or 4 (safety population) (low certainty).

• Platinum‐containing regimens for triple‐negative metastatic breast cancer 2020 · Cochrane Headline outcomes only
  RR 3.8
  5 studies · 843 participants
  Low

Intervention not reported

The intervention may leads to lower hair loss (safety population) (low certainty).

• Platinum‐containing regimens for triple‐negative metastatic breast cancer 2020 · Cochrane Headline outcomes only
  RR 0.33
  2 studies · 602 participants
  Low

Intervention not reported

The intervention probably leads to higher leukopaenia (safety population) (moderate certainty).

• Platinum‐containing regimens for triple‐negative metastatic breast cancer 2020 · Cochrane Headline outcomes only
  RR 1.09
  5 studies · 843 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in all‐cause mortality (low certainty).

• Cryotherapy for liver metastases 2019 · Cochrane Headline outcomes only
  RR 0.88 [0.77, 1.02]
  1 study · 123 participants
  Low

Intervention not reported

The review found no eligible studies for this question.

• Cryotherapy for liver metastases 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The intervention led to higher all adverse events and complications; GRADE not reported.

• Cryotherapy for liver metastases 2019 · Cochrane Headline outcomes only
  RR 1.15
  1 participants
  GRADE not reported

Intervention not reported

The review found no eligible studies for this question.

• Cryotherapy for liver metastases 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

• Cryotherapy for liver metastases 2019 · Cochrane Headline outcomes only
  30
  69 participants
  Low

mTOR inhibitors vs chemotherapy/hormone therapy

mTOR inhibitors may leads to higher progression‐free survival: first‐line trials ( compared with chemotherapy/hormone therapy (low certainty).

• PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer 2019 · Cochrane Headline outcomes only
  HR 1.43 [1.06, 1.93]
  1 study · 231 participants
  Low

mTOR inhibitors vs chemotherapy/hormone therapy

The review found no eligible studies for this question.

• PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

mTOR inhibitors vs chemotherapy/hormone therapy

mTOR inhibitors probably leads to lower progression‐free survival: second/third‐line trials ( compared with chemotherapy/hormone therapy (moderate certainty).

• PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer 2019 · Cochrane Headline outcomes only
  HR 0.53 [0.31, 0.91]
  1 study · 95 participants
  Moderate

mTOR inhibitors vs chemotherapy/hormone therapy

mTOR inhibitors showed no clear difference in haematological toxicities ‐ Anaemia compared with chemotherapy/hormone therapy (low certainty).

• PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer 2019 · Cochrane Headline outcomes only
  RR 1.42 [0.83, 2.44]
  2 studies · 357 participants
  Low

mTOR inhibitors vs chemotherapy/hormone therapy

mTOR inhibitors may leads to higher skin toxicities ‐ Mucositis compared with chemotherapy/hormone therapy (low certainty).

• PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer 2019 · Cochrane Headline outcomes only
  RR 10.42 [1.34, 80.74]
  2 studies · 357 participants
  Low

mTOR inhibitors vs chemotherapy/hormone therapy

mTOR inhibitors showed no clear difference in respiratory toxicity ‐ Interstitial pneumonitis compared with chemotherapy/hormone therapy (low certainty).

• PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer 2019 · Cochrane Headline outcomes only
  RR 7.36 [0.88, 61.52]
  2 studies · 357 participants
  Low

mTOR inhibitors vs chemotherapy/hormone therapy

mTOR inhibitors showed no clear difference in overall survival: first‐line trials ( compared with chemotherapy/hormone therapy (low certainty).

• PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer 2019 · Cochrane Headline outcomes only
  HR 1.32 [0.98, 1.78]
  1 study · 231 participants
  Low

mTOR inhibitors vs chemotherapy/hormone therapy

mTOR inhibitors showed no clear difference in overall survival: second/third‐line trials ( compared with chemotherapy/hormone therapy (low certainty).

• PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer 2019 · Cochrane Headline outcomes only
  HR 1.06 [0.7, 1.61]
  1 study · 130 participants
  Low

mTOR inhibitors vs chemotherapy/hormone therapy

mTOR inhibitors showed no clear difference in objective response rate: first‐line trial compared with chemotherapy/hormone therapy (low certainty).

• PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer 2019 · Cochrane Headline outcomes only
  RR 0.93 [0.75, 1.17]
  1 study · 231 participants
  Low

mTOR inhibitors vs chemotherapy/hormone therapy

mTOR inhibitors showed no clear difference in objective response rate: second/third‐line trials compared with chemotherapy/hormone therapy (low certainty).

• PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer 2019 · Cochrane Headline outcomes only
  RR 0.22 [0.01, 4.4]
  1 study · 61 participants
  Low

Long‐term GnRH agonist therapy vs no additional therapy

It is very uncertain whether long‐term GnRH agonist therapy changes live birth rate compared with no additional therapy (very low certainty).

• Long‐term GnRH agonist therapy before in vitro fertilisation (IVF) for improving fertility outcomes in women with… 2019 · Cochrane Headline outcomes only
  RR 0.48 [0.26, 0.87]
  1 study · 147 participants
  Very low

Long‐term GnRH agonist therapy vs no additional therapy

It is very uncertain whether long‐term GnRH agonist therapy changes complication rate compared with no additional therapy (very low certainty).

• Long‐term GnRH agonist therapy before in vitro fertilisation (IVF) for improving fertility outcomes in women with… 2019 · Cochrane Headline outcomes only
  Peto OR 1.23 [0.37, 4.14]
  3 studies · 318 participants
  Very low